» Articles » PMID: 33998853

An Approach to Biomarker Discovery of Cannabis Use Utilizing Proteomic, Metabolomic, and Lipidomic Analyses

Overview
Specialty Pharmacology
Date 2021 May 17
PMID 33998853
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Relatively little is known about the molecular pathways influenced by cannabis use in humans. We used a multi-omics approach to examine protein, metabolomic, and lipid markers in plasma differentiating between cannabis users and nonusers to understand markers associated with cannabis use. Eight discordant twin pairs and four concordant twin pairs for cannabis use completed a blood draw, urine and plasma toxicology testing, and provided information about their past 30-day cannabis use and other substance use patterns. The 24 twins were all non-Hispanic whites. Sixty-six percent were female. Median age was 30 years. Fifteen participants reported that they had used cannabis in the last 30 days, including eight participants that used every day or almost every day (29-30 of 30 days). Of these 15 participants, plasma 11-nor-9-carboxy-Δ-tetrahydrocannabinol (THC-COOH) and total tetrahydrocannabinol (THC) concentrations were detectable in 12 participants. Among the eight "heavy users" the amount of total THC (sum of THC and its metabolites) and plasma THC-COOH concentrations varied widely, with ranges of 13.1-1713 ng/mL and 2.7-284 ng/mL, respectively. A validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay measured plasma THC-COOH, THC, and other cannabinoids and metabolites. Plasma THC-COOH was used as the primary measure. Expression levels of 1305 proteins were measured using SOMAScan assay, and 34 lipid mediators and 314 metabolites were measured with LC-MS/MS. Analyses examined associations between markers and THC-COOH levels with and without taking genetic relatedness into account. Thirteen proteins, three metabolites, and two lipids were identified as associated with THC-COOH levels. Myc proto-oncogene was identified as associated with THC-COOH levels in both molecular insight and potential marker analyses. Five pathways (interleukin-6 production, T lymphocyte regulation, apoptosis, kinase signaling pathways, and nuclear factor kappa-light-chain-enhancer of activated B cells) were linked with molecules identified in these analyses. THC-COOH levels are associated with immune system-related pathways. This study presents a feasible approach to identify additional molecular markers associated with THC-COOH levels.

Citing Articles

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.

Villate A, Olivares M, Usobiaga A, Unzueta-Larrinaga P, Barrena-Barbadillo R, Callado L Sci Rep. 2024; 14(1):31492.

PMID: 39733019 PMC: 11682106. DOI: 10.1038/s41598-024-83288-5.


An exploratory study of metabolomics in endogenous and cannabis-use-associated psychotic-like experiences in adolescence.

Kurkinen K, Karkkainen O, Lehto S, Luoma I, Kraav S, Kivimaki P Transl Psychiatry. 2024; 14(1):466.

PMID: 39511135 PMC: 11543670. DOI: 10.1038/s41398-024-03163-9.


The relationship between cannabis use and taurine: A MRS and metabolomics study.

Newman S, Schnakenberg Martin A, Raymond D, Cheng H, Wilson L, Barnes S PLoS One. 2022; 17(6):e0269280.

PMID: 35653401 PMC: 9162360. DOI: 10.1371/journal.pone.0269280.


A Proteomic View of Cellular and Molecular Effects of Cannabis.

Abyadeh M, Gupta V, Paulo J, Gupta V, Chitranshi N, Godinez A Biomolecules. 2021; 11(10).

PMID: 34680044 PMC: 8533448. DOI: 10.3390/biom11101411.


Genetic basis of cannabis use: a systematic review.

Hillmer A, Chawar C, Sanger S, DElia A, Butt M, Kapoor R BMC Med Genomics. 2021; 14(1):203.

PMID: 34384432 PMC: 8359088. DOI: 10.1186/s12920-021-01035-5.

References
1.
Nagarkatti P, Pandey R, Rieder S, Hegde V, Nagarkatti M . Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2010; 1(7):1333-49. PMC: 2828614. DOI: 10.4155/fmc.09.93. View

2.
Klepacki J, Klawitter J, Klawitter J, Karimpour-Fard A, Thurman J, Ingle G . Amino acids in a targeted versus a non-targeted metabolomics LC-MS/MS assay. Are the results consistent?. Clin Biochem. 2016; 49(13-14):955-61. PMC: 6047903. DOI: 10.1016/j.clinbiochem.2016.06.002. View

3.
Galan-Ganga M, Garcia-Yague A, Lastres-Becker I . Role of MSK1 in the Induction of NF-κB by the Chemokine CX3CL1 in Microglial Cells. Cell Mol Neurobiol. 2019; 39(3):331-340. PMC: 11469855. DOI: 10.1007/s10571-019-00664-w. View

4.
Onwuameze O, Nam K, Epping E, Wassink T, Ziebell S, Andreasen N . MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med. 2012; 43(3):619-31. PMC: 3847818. DOI: 10.1017/S0033291712001559. View

5.
Eisen S, Chantarujikapong S, Xian H, Lyons M, Toomey R, True W . Does marijuana use have residual adverse effects on self-reported health measures, socio-demographics and quality of life? A monozygotic co-twin control study in men. Addiction. 2002; 97(9):1137-44. DOI: 10.1046/j.1360-0443.2002.00120.x. View